TRCT
TELO icon

Tower Research Capital (TRC)’s Telomir Pharmaceuticals TELO Stock Holding History

Tower Research Capital (TRC)’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,251
Closed -$1.74K – 5685
2025
Q3 		$1.74K Sell
1,251
-7,395
-86% -$11.2K ﹤0.01% 4735
2025
Q2 		$10.8K Buy
8,646
+5,929
+218% +$13.7K ﹤0.01% 3934
2025
Q1 		$8.78K Buy
2,717
+362
+15% +$1.58K ﹤0.01% 3852
2024
Q4 		$9.7K Buy
2,355
+857
+57% +$4.04K ﹤0.01% 3883
2024
Q3 		$9.62K Buy
1,498
+550
+58% +$2.68K ﹤0.01% 3852
2024
Q2 		$4.56K Buy
+948
New +$5.92K ﹤0.01% 4767

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

Tower Research Capital (TRC)'s TELO Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of Telomir Pharmaceuticals (TELO) in Q4 2025, closing a stake of 1,251 shares — an estimated $1.74K sold.

Tower Research Capital (TRC) first reported a position in TELO in Q2 2024 and held it in 6 quarters. The position peaked at $10.8K in Q2 2025. 33 funds tracked by Wall St. Rank hold TELO as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining Telomir Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,251 Telomir Pharmaceuticals shares in Q4 2025, an estimated $1.74K.
  • Tower Research Capital (TRC) first reported a position in Telomir Pharmaceuticals in Q2 2024 and held it in 6 quarters.
  • Tower Research Capital (TRC)'s Telomir Pharmaceuticals position peaked at $10.8K in Q2 2025.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.